Quarterly ResultJun 15, 2026, 04:17 PM
PURE Bioscience Reports Q3 Results: Revenue Up, Net Loss Continues
AI Summary
PURE Bioscience, Inc. filed its 10-Q report for the period ending April 30, 2026. The company reported an increase in total revenue to $1,658,000 for the nine months ended April 30, 2026, up from $1,438,000 in the prior year, driven by higher net product sales. However, the company continued to incur net losses, with a loss of $1,873,000 for the nine-month period, compared to $2,067,000 in the prior year. The company also completed a $1.0 million private placement financing and has significant convertible notes payable to related parties.
Key Highlights
- PURE Bioscience, Inc. reported a net loss of $1,873,000 for the nine months ended April 30, 2026, compared to a net loss of $2,067,000 for the same period in 2025.
- Total revenue for the nine months ended April 30, 2026, was $1,658,000, an increase from $1,438,000 in the prior year.
- Net product sales increased to $1,656,000 for the nine months ended April 30, 2026, from $1,435,000 in the prior year.
- Cash and cash equivalents increased to $983,000 as of April 30, 2026, from $334,000 as of July 31, 2025.
- The company completed a private placement financing on April 30, 2026, raising $1.0 million by issuing 18,131,096 shares of common stock.
- Convertible notes payable to related parties totaled $6,497,000 as of April 30, 2026, including accrued interest.
- Stockholders' deficiency was $5,839,000 as of April 30, 2026, compared to $5,116,000 as of July 31, 2025.
Price Impact
More from PURE